AI assistant
Sending…
GALECTIN THERAPEUTICS INC — Director's Dealing 2012
May 25, 2012
33422_dirs_2012-05-25_4475859f-95f2-4e2b-befb-32e19fa7a736.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2012-03-06
Reporting Person: MCGAULEY THOMAS (Chief Financial Officer)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Warrants (right to buy) | $4.50 | 2014-05-25 | Common Stock (1250) | Direct |
Footnotes
F1: Reflects application of Issuer's 1-for-6 reverse stock split effective 02/22/2012
More from GALECTIN THERAPEUTICS INC
Earnings Release
2026
May 15
Interim / Quarterly Report
2026
May 15
Capital/Financing Update
2026
Mar 31
Earnings Release
2026
Mar 31
Annual Report
2026
Mar 31
Director's Dealing
2026
Mar 17
Director's Dealing
2026
Mar 17
Board/Management Information
2026
Mar 17
Director's Dealing
2026
Feb 9
Board/Management Information
2026
Jan 21